Stocks and Investing
Stocks and Investing
Thu, July 29, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Elliot Wilbur Maintained (TEVA) at Buy with Decreased Target to $14 on, Jul 29th, 2021
Elliot Wilbur of Raymond James, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Buy with Decreased Target from $15 to $14 on, Jul 29th, 2021.
Elliot has made no other calls on TEVA in the last 4 months.
There is 1 other peer that has a rating on TEVA. Out of the 1 peers that are also analyzing TEVA, all agrees with Elliot's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Kevin Caliendo of "UBS" Downgraded from Strong Buy to Hold and Decreased Target to $11 on, Tuesday, May 4th, 2021
Contributing Sources